source
- TCGX raises $600 million to fund Asian biotech startupsInvestment firm TCGX announced a new $600 million Asia Life Sciences Fund I aimed at supporting biotech companies across the region. The fund will operate separately but in close coordination with…
- Atsena reports early efficacy signals for gene therapy ATSN-201 in X-linked retinoschisis trialAtsena Therapeutics presented data from the early parts of its Lighthouse gene therapy trial for X-linked retinoschisis (XLRS) at the American Academy of Ophthalmology meeting. The trial administe…